18 research outputs found
Track E Implementation Science, Health Systems and Economics
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138412/1/jia218443.pd
Recommended from our members
Track A Basic Science
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138319/1/jia218438.pd
Track D Social Science, Human Rights and Political Science
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138414/1/jia218442.pd
Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort
OBJECTIVE: Prior studies have shown improved neurocognition with initiation of antiretroviral treatment (ART) in HIV. We hypothesized that stopping ART would be associated with poorer neurocognitive function.
METHODS: Neurocognitive function was assessed as part of ACTG 5170, a multicenter, prospective observational study of HIV-infected subjects who elected to discontinue ART. Eligible subjects had CD4 count >350 cells/mm(3), had HIV RNA viral load or=2 drugs) for >or=6 months. Subjects stopped ART at study entry and were followed for 96 weeks with a neurocognitive examination.
RESULTS: A total of 167 subjects enrolled with a median nadir CD4 of 436 cells/mm(3) and 4.5 median years on ART. Significant improvements in mean neuropsychological scores of 0.22, 0.39, 0.53, and 0.74 were found at weeks 24, 48, 72, and 96 (all p < 0.001). In the 46 subjects who restarted ART prior to week 96, no significant changes in neurocognitive function were observed.
CONCLUSION: Subjects with preserved immune function found that neurocognition improved significantly following antiretroviral treatment (ART) discontinuation. The balance between the neurocognitive cost of untreated HIV viremia and the possible toxicities of ART require consideration.
CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that discontinuing ART is associated with an improvement in 2 neuropsychological tests (Trail-Making Test A & B and the Wechsler Adult Intelligence Scale-Revised Digit Symbol subtest) for up to 96 weeks. Resuming ART was not associated with a decline in these scores for up to 45 weeks
Clinical and laboratory findings of disseminated Mycobacterium avium complex infection (DMAC) in a pair matched case-control study Manifestaçþes clĂnicas e laboratoriais da infecção disseminada pelo complexo Mycobacterium avium (DMAC) em um estudo caso/controle pareado
A pair matched case/control study was conducted from January 1991 to 30 June 1992 in order to define clinical and laboratory findings associated with DMAC infection in AIDS patients. Since DMAC infection is usually associated with advanced immunodeficiency, and therefore also with other opportunistic illnesses, in addition to the number of CD4+ lymphocytes, cases and controls were matched using the following criteria: date of AIDS diagnosis and antiretroviral therapy, number and severity of associated opportunistic infections and, whenever possible, type of Pneumocystis carinii prophylaxis, age and gender, in this order of relevance. Cases (defined as patients presenting at least one positive culture for MAC at a normally sterile site) and controls presented CD4+ lymphocyte counts below 50 cel/mm3. A significantly higher prevalence of general, digestive and respiratory signs, increased LDH levels, low hemoglobin levels and CD4+ cell counts were recorded for cases when compared to controls. Increases in <FONT FACE="Symbol">g</font>GT and alkaline phosphatase levels seen in cases were also recorded for controls. In conclusion, the strategy we used for selecting controls allowed us to detect laboratory findings associated to DMAC infection not found in other advanced immunossupressed AIDS patients without DMAC.<br>Um estudo caso/controle pareado foi realizado no perĂodo compreendido entre janeiro de 1991 e junho de 1992, a fim de determinar a associação de manifestaçþes clĂnicas e laboratoriais com a DMAC em pacientes com AIDS. Como a DMAC ĂŠ habitualmente associada com imunodeficiĂŞncia avançada e portanto tambĂŠm com outras doenças oportunistas, alĂŠm do nĂşmero de linfĂłcitos CD4+, casos e controles foram pareados utilizando-se os seguintes critĂŠrios: data do diagnĂłstico de AIDS e terapĂŞutica anti-retroviral, nĂşmero e gravidade das infecçþes oportunistas associadas e quando possĂvel, tipo de profilaxia para Pneumocystis carinii, idade e sexo, nesta ordem de importância. Os casos (definidos como pacientes que apresentaram ao menos uma cultura positiva para MAC em sĂtio normalmente estĂŠril) e controles apresentaram contagem de linfĂłcitos CD4+ abaixo de 50/mm3. Uma prevalĂŞncia significativamente alta de sinais gerais digestivos e respiratĂłrios, elevação nos nĂveis de DHL, nĂveis baixos de hemoglobina e cĂŠlulas CD4+ foi observada nos casos comparados aos controles. A elevação da <FONT FACE="Symbol">g</font>GT e fosfatase alcalina observada nos casos foram tambĂŠm observadas nos controles. Em conclusĂŁo, a estratĂŠgia utilizada por nĂłs para selecionar os controles nos permitiu detectar exames laboratoriais associados Ă DMAC nĂŁo observadas em outros pacientes com AIDS e imunossupressĂŁo avançada sem DMAC
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.
Contains fulltext :
81235.pdf (publisher's version ) (Closed access)Several dose-finding studies of boosted protease inhibitors have demonstrated that doses lower than those recommended in Caucasian populations exhibit in the Thai population similar pharmacokinetic (PK) properties with sustained virological suppression but reduced toxicity. We therefore evaluated the PK profiles of lower than the standard doses of atazanavir/ritonavir (ATV/RTV) in 22 adult Thai patients with well-suppressed human immunodeficiency virus 1 (HIV-1) infection. The PK parameters of ATV/RTV at a dosage of 200/100 mg once daily, plus two nucleoside reverse transcriptase inhibitors, were significantly lower than those associated with a dosage of 300/100 mg once daily in the same patients. In addition, the PK parameters for the lower dosage in these Thai patients were comparable to historical data from Caucasian cohorts who received the standard dose of ATV/RTV (300/100 mg). None of the patients showed subtherapeutic values of <0.15 mg/l at any time point. Bilirubin concentration decreased significantly after dose reduction, and viral load remained at <50 copies/ml in all subjects. Therefore, ATV/RTV at a dose of 200/100 mg once daily (plus appropriate backbone medication) warrants further long-term efficacy studies, particularly in patients of Thai and other Asian ethnicities